ArticleResearch square2026
Yellow Fever Outbreaks and Reactive Vaccination in Africa, 2010-2025: A Scoping Review and Analysis.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Containing yellow fever (YF) outbreaks rapidly through reactive vaccination campaigns (RVCs) is a key objective of the 2017-2026 Eliminate Yellow Fever Epidemics (EYE) strategy. We conducted a scoping review and quantitative analysis using grey and peer-reviewed literature on YF outbreaks in Africa (2010-2025) to compare how factors including outbreak size and timing of RVCs have changed pre- and post-EYE strategy. The overall median time between YF index case and RVC was 90.5 days (interquartile range [IQR]: 53.8-113.2), with medians of 108 days (IQR 59-111) for 2010-2016 and 79 days (IQR 51-114.5) for 2017-2025. The median (IQR) reported cases per outbreak was 91 (IQR: 16-276) in 2010-2016 and 94 (49-377) in 2017-2025, with case fatality ratios (CFRs) of 8.5% (standard error [SE]: 2.1%) and 4.9% (SE: 2.9%), respectively. High morbidity and mortality for YF persist in Africa, and more timely RVCs will be required to achieve YF control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.